These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17612756)

  • 21. [Treatment of lipid disorders in metabolic syndrome and type 2 diabetes. The place for fibrates].
    Cybulska B; Kłosiewicz-Latoszek L
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II45-50. PubMed ID: 19813336
    [No Abstract]   [Full Text] [Related]  

  • 22. [Depot calcium antagonist. General practice study confirms good tolerance].
    MMW Fortschr Med; 2003 Jan; 145(5):56. PubMed ID: 12619222
    [No Abstract]   [Full Text] [Related]  

  • 23. [The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
    Widimský J
    Vnitr Lek; 2009 Feb; 55(2):123-30. PubMed ID: 19348394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
    Zidek W
    MMW Fortschr Med; 2004 Jan; 146(1-2):37-8. PubMed ID: 18437867
    [No Abstract]   [Full Text] [Related]  

  • 25. [The usefulness of long-acting calcium channel blocker for hypertensive patients with metabolic syndrome].
    Ishida A; Ohya Y
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():582-6. PubMed ID: 21766664
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
    J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey.
    Kjeldsen SE; Naditch-Brule L; Perlini S; Zidek W; Farsang C
    J Hypertens; 2008 Oct; 26(10):2064-70. PubMed ID: 18806632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic syndrome: diabetes and cardiovascular disease.
    Gupta S; Gupta BM
    Indian Heart J; 2006; 58(2):149-52. PubMed ID: 18989060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethanol effects on drug release from Verapamil Meltrex, an innovative melt extruded formulation.
    Roth W; Setnik B; Zietsch M; Burst A; Breitenbach J; Sellers E; Brennan D
    Int J Pharm; 2009 Feb; 368(1-2):72-5. PubMed ID: 18992310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolic syndrome in hypertension: European society of hypertension position statement.
    Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G;
    J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
    Zanchetti A; Hennig M; Baurecht H; Tang R; Cuspidi C; Carugo S; Mancia G
    J Hypertens; 2007 Dec; 25(12):2463-70. PubMed ID: 17984668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
    Aksnes TA; Kjeldsen SE; Rostrup M; Störset O; Hua TA; Julius S
    J Hum Hypertens; 2008 Aug; 22(8):520-7. PubMed ID: 18509347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up.
    Liu SJ; Guo ZR; Hu XS; Wu M; Chen FM; Kang GD; Zhou H; Guo L
    Diabetes Res Clin Pract; 2008 Jul; 81(1):117-23. PubMed ID: 18485514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of new-onset diabetes mellitus in patients with hypertension treated with beta blockers.
    Ram CV
    Am J Cardiol; 2008 Jul; 102(2):242-4; author reply 244-8. PubMed ID: 18602529
    [No Abstract]   [Full Text] [Related]  

  • 35. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
    Landmark K; Reikvam A
    Tidsskr Nor Laegeforen; 2009 Sep; 129(17):1740-4. PubMed ID: 19756054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of arterial hypertension with the use of trandolapril for patients with metabolic syndrome].
    Samsonova NG; Mikheeva OM; Nilova TV
    Eksp Klin Gastroenterol; 2007; (1):51-4. PubMed ID: 17547114
    [No Abstract]   [Full Text] [Related]  

  • 37. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 38. [Metabolic syndrome as a precursor of diabetes mellitus type 2 and cardiovascular diseases].
    Shestakova MV; Butrova SA; Sukhareva OIu
    Ter Arkh; 2007; 79(10):5-8. PubMed ID: 18154136
    [No Abstract]   [Full Text] [Related]  

  • 39. [The application of 4-aminopyridine in calcium channel inhibitors acute poisoning].
    Fiszer M; Kołaciński Z; Rechciński T
    Przegl Lek; 2007; 64(4-5):293-7. PubMed ID: 17724889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and predictors of metabolic syndrome in non-obese Asian Indians with newly detected type 2 diabetes mellitus.
    Dhanaraj E; Bhansali A; Jaggi S; Dutra P; Jain S; Tiwari P; Ramarao P
    J Indian Med Assoc; 2008 Jun; 106(6):366-8, 370-2. PubMed ID: 18839648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.